Moleculin Biotech (NASDAQ: MBRX) has announced that it has entered into a research and material transfer agreement with non-profit CIC biomaGUNE for preclinical research evaluating Annamycin for the treatment of glioblastoma multiforme (GBM), a form of brain cancer.
Under the terms of the agreement Moleculin will supply Annamycin and Jesús Ruiz-Cabello, principal investigator at CIC biomaGUNE, will conduct the planned preclinical research. The studies covered under this agreement will evaluate tumor progression following intra-arterial delivery of liposomal Annamycin (L-Annamycin) and Free-Annamycin as compared to Doxil and Free-doxorubicin in mouse models.
In a statement, Walter Klemp, chairman and CEO of Moleculin, commented, “We are excited to further expand our efforts to advance and develop Annamycin across a number of investigator-initiated studies. Annamycin has demonstrated clinical activity in acute myeloid leukemia and soft tissue sarcomas while also showing potential in preclinical models in pancreatic, GBM, and certain liver cancers amongst others.”
Mr. Klemp added, “GBM remains an area of profound unmet medical need, with current therapies offering only limited survival benefit and no meaningful long-term solutions. Collaborating with the premier research team at CIC biomaGUNE provides an important opportunity to explore Annamycin’s potential to overcome the challenges of drug delivery and resistance in central nervous system tumors. This work highlights the potential breadth of Annamycin and underscores our commitment to advancing innovative therapies for patients facing cancers with few or no effective options.”
